Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study
REUTERS: A lower dosage of non-opioid pain reliever established by Pfizer Inc and Eli Lilly and Co stopped working to satisfy primary objectives in a late-stage research study in clients with moderate-to-severe osteoarthritis of the hip or knee, the business stated on Thursday. The drug, tanezumab, comes from a brand-new classification of discomfort medications that … Read more